Newsroom

Sorted by: Latest

-

MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal

LYON, France--(BUSINESS WIRE)--MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal....
-

MaaT Pharma annonce la publication de données rétrospectives en troisième ligne dans la maladie aiguë du greffon contre l’hôte (aGvH) issues de l’étude CHRONOS dans la revue Bone Marrow Transplantation

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET) visant à améliorer la survie, annonce aujourd’hui la publication de CHRONOS, une étude de cohorte rétrospective multicentrique évaluant les résultats en vie réelle des traitements systémiques de troisième ligne (hors microbiothérapie) chez 59 patients atteints de GI-aGvH réfract...
-

Eurofins Announces the Cancellation of 6.163M Repurchased Shares

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (the “Company” or “Eurofins”) (EUFI.PA) (Paris:ERF) announces that its Board of Directors has decided on the cancellation of 6,163,000 shares, representing 3.38% of the Company’s share capital, that were repurchased as part of its share buyback programmes, which began in October 2022. The cancellation of shares is in line with, among other objectives, the Company’s intention to reduce the share capital as authorised by shareho...
-

SMAIO annonce le transfert de son contrat de liquidité auprès de Portzamparc (Groupe BNP Paribas)

DALLAS & LYON--(BUSINESS WIRE)--Regulatory News: SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, Code ISIN : FR0014005I80 / Mnémonique : ALSMA, éligible PEA-PME), une société franco-américaine spécialisée dans la chirurgie rachidienne complexe proposant une solution intégrée pré, intra et postopératoire basée sur un logiciel de planification 3D, des implants adaptatifs et des services associés, annonce avoir confié à Portzamparc (Groupe BNP Paribas), à c...
-

RevolKa Reimagines Antibody Engineering with "RevoAb®"

SENDAI, Japan--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibody yields. RevoAb®: The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization se...
-

Versigent Launches as New Publicly Traded Company

SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--Versigent PLC (NYSE: VGNT) today announced the completion of its separation from Aptiv PLC (NYSE: APTV) and its launch as an independent, publicly traded company. Versigent’s shares will begin trading on the New York Stock Exchange (NYSE) under the ticker symbol “VGNT” today where members of the Company’s leadership team are scheduled to ring the Opening Bell. Versigent is a global leader in the design, manufacturing, and delivery of low- and high-vol...
-

No one listened. Then a Dante Labs Whole Genome Report Gave a Single Mother's Two Children a Name for Their Disease and Access to the Specialists They Needed

NEW YORK--(BUSINESS WIRE)--For years, Susan watched her two children collapse without warning. Episodes of sudden, full-body muscle weakness that came and went — sometimes lasting minutes, sometimes hours. Between episodes, they looked like any other healthy kids. And that was the problem. Susan, a single mother in a small town in New Zealand, took her children to doctor after doctor. Blood panels came back normal. She was told the symptoms were stress-related. No referrals. No follow-up. No an...
-

Nessuno ascoltava. Poi il genoma completo di Dante Labs ha dato ai due figli di una madre single un nome per la loro malattia e l’accesso agli specialisti di cui avevano bisogno

NEW YORK--(BUSINESS WIRE)--Per anni, Susan vedeva i suoi due figli crollare senza preavviso. Episodi di improvvisa debolezza muscolare in tutto il corpo — a volte duravano minuti, a volte ore. Tra un episodio e l'altro, sembravano bambini sani come gli altri. Ed era proprio questo il problema. Susan, una madre single in una piccola città della Nuova Zelanda, ha portato i suoi figli da molti medici. I valori del sangue erano nella norma. Le è stato detto che i sintomi erano legati allo stress. N...
-

ExaGrid es finalista en los premios Network Computing Awards 2026

MARLBOROUGH, Massachusetts--(BUSINESS WIRE)--ExaGrid®, el principal proveedor independiente de almacenamiento para copias de seguridad del mundo, especializado en servicios de almacenamiento por niveles con la seguridad más completa y un sistema de retención con bloqueo temporal con IA para asegurar la recuperación ante ransomware, ha anunciado hoy que ha sido nominada en 11 categorías de los premios anuales Network Computing Awards. ExaGrid ya es el finalista en las categorías siguientes: Prod...
-

エクサグリッド、「Network Computing Awards 2026」のファイナリストに選出

マサチューセッツ州マールボロ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 階層型バックアップストレージを提供し、ランサムウェア復旧のための最も包括的なセキュリティーおよびAI搭載リテンションタイムロック機能を備える世界最大の独立系バックアップストレージベンダーであるエクサグリッド®は、年次開催のNetwork Computing Awardsにおいて11部門でノミネートされたことを発表しました。 エクサグリッドは、以下の各部門においてファイナリストに選出されました。 Data Protection Product of the Year(データ保護製品オブザイヤー) The Return On Investment Award(投資収益率賞) Air Gapped Ransomware Recovery Product of the Year(エアギャップ型ランサムウェア復旧製品オブザイヤー) Storage Product of the Year(ストレージ製品オブザイヤー) Hardware Product of the Year(ハードウエア製品オブザイヤー)...